Hormone therapy as a management strategy for lung metastasis after 5 years of endometrial cancer: A case report and literature review. Issue 51 (December 2017)

• Record Type: Journal Article
• Authors: Zhao, Huifang; Yao, Yushuang; Yang, Hongjuan; Ma, Dehua; Chen, Aiping
• Other Names: NA. section editor.
• Is Part Of: Medicine. Volume 96:Issue 51(2017)
• Publication Date: 2017-12
• Subjects: endometrial cancer -- hormone therapy -- lung metastasis -- recurrence; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000009223
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: Endometrial cancer patients with lung metastases are rare, and more rarely with long-term management of progesterone after recurrence. Patient concerns: Informed consent of the patients and their families. Diagnoses: Endometrial cancer (IVB) (Refer to 2009 FIGO stag of endometrial cancer). Interventions: the patient was treated with Megestrol Acetate Dispersible Tablets (trade name Yilizhi), 160 mg, orally, once daily, without interruption. Outcomes: The patient has been treated with progesterone therapy for stable conditions and her survival time is already roughly a decade (December 2006–October 2016). Lessons: Hormone therapy may as a long-term management for hormone receptor-positive patients with recurrent endometrial cancer.